Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma ASZLDPF 61 Intrinsic Value: Projected FCF is $41.42 as of Sep. 21, 2026. GuruFocus rates ZLDPF with a GF Score™ of 61/100 and a GF Value™ of $2,518.08 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 257 Biotechnology companies, Zealand Pharma AS ranks better than 77.04% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-21), Zealand Pharma AS's Intrinsic Value: Projected FCF is $41.42. The stock price of Zealand Pharma AS is $43.00. Therefore, Zealand Pharma AS's Price-to-Intrinsic-Value-Projected-FCF of today is 1.0.
The historical rank and industry rank for Zealand Pharma AS's Intrinsic Value: Projected FCF or its related term are showing as below:
ZLDPF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.04 Med: 1.74 Max: 117.13
Current: 1.04
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Zealand Pharma AS was 117.13. The lowest was 1.04. And the median was 1.74.
ZLDPF's Price-to-Projected-FCF is ranked better than 77.04% of 257
companies
in the Biotechnology industry
Industry Median: 2.19
vs ZLDPF: 1.04
Zealand Pharma AS (OTCPK:ZLDPF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Zealand Pharma AS's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
43.00
/
40.829426537234
=
1.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS Intrinsic Value: Projected FCF Related Terms
Zealand Pharma AS Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS Intrinsic Value: Projected FCF Chart
ZLDPF vs VRTX, REGN, MRNA: Intrinsic Value: Projected FCF Comparison
For the Biotechnology subindustry, Zealand Pharma AS's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Price-to-Projected-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Price-to-Projected-FCF falls into.
Zealand Pharma AS Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $41.42 mean?
Zealand Pharma AS (ZLDPF) has a Intrinsic Value: Projected FCF of $41.42 as of Sep. 21, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Zealand Pharma AS and its competitors. According to the industry distribution chart, Zealand Pharma AS ranks #59 out of 257 companies in the Biotechnology industry, placing it in the top 23%.
Is Zealand Pharma AS's Intrinsic Value: Projected FCF too high?
Zealand Pharma AS's current Intrinsic Value: Projected FCF is $41.42. The Biotechnology industry median Intrinsic Value: Projected FCF is 2.19. Zealand Pharma AS's value of $41.42 is 1791.3% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #59 out of 257 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Intrinsic Value: Projected FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #59 out of 257 companies for Intrinsic Value: Projected FCF. This places Zealand Pharma AS in the top 23% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 2.19. Zealand Pharma AS's value of $41.42 is 1791.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Biotechnology company?
The median Intrinsic Value: Projected FCF among Biotechnology companies is 2.19, based on 257 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Intrinsic Value: Projected FCF of $41.42 is 1791.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Intrinsic Value: Projected FCF is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Intrinsic Value: Projected FCF is $41.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $2,518.08, compared to a current price of $43.00 — trading 98.3% below its estimated fair value. The current Intrinsic Value: Projected FCF is $41.42 and 1791.3% above the Biotechnology industry median of 2.19. Zealand Pharma AS's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Intrinsic Value: Projected FCF is $41.42 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $43.00 is trading 98.3% below its estimated GF Value™ of $2,518.08.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
Intrinsic Value: Projected FCF: $41.42
GF Value™: $2,518.08 vs. price of $43.00 (98.3% below fair value)
Industry Position: 1791.3% above the Biotechnology median (#59 of 257)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
61GF Score
Get the complete analysis for ZLDPF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
